This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

Sponsored by GT Medical Technologies, Inc.

About this trial

Last updated 2 years ago

Study ID

GTM-101

Status

Recruiting

Type

Observational [Patient Registry]

Placebo

No

Accepting

18-75 Years
All
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Started 5 years ago

What is this trial about?

The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.

What are the participation requirements?

Yes

Inclusion Criteria

1. Patients who undergo maximum safe resection of intracranial neoplasm(s) AND implantation of GammaTiles.

2. Willing and able to provide informed consent and to participate in all evaluations.

No

Exclusion Criteria

1. Inability to undergo pre-operative and post-operative imaging for disease and implant assessment.

2. Major medical or psychiatric illness, which, in the investigator's opinion would prevent completion of treatment, ability to complete assessments at the time of enrollment, and/or interfere with follow ups.

3. Lack of English language fluency sufficient to allow for completion of neurocognitive and QOL tests (which are in English).

Locations

Location

Status

Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Not yet recruiting
Not yet recruiting
Active, not recruiting
Withdrawn